<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806013</url>
  </required_header>
  <id_info>
    <org_study_id>SIMM-080601</org_study_id>
    <nct_id>NCT00806013</nct_id>
  </id_info>
  <brief_title>Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide</brief_title>
  <official_title>Study the Effects of CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide in Healthy Chinese Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on
      the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide
      pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on
      CYP2C9 genotype may improve antidiabetic treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>CYP2C9*1/*1 and CYP2C19*1/*1 alleles carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>CYP2C19 PMs (CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>CYP2C9*1/*3 and CYP2C19*1/*1 alleles carrier</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The whole blood samples of each person are stored at -80â„ƒ.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male Chinese subjects with different geontype of CYP2C9 and CYP2C19 were enrolled in this
        study. They are divided into three groups by different geontype.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nonsmokers and in good health

        Exclusion Criteria:

          -  family history of diabetes mellitus

          -  taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>27 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Tan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Institute of Materia Medica, Chinese Academy of Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The second hospital to Liaoning University of TCM</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://english.simm.cas.cn/</url>
    <description>Our organization</description>
  </link>
  <link>
    <url>http://english.cas.cn/</url>
    <description>Chinese Academy of Sciences</description>
  </link>
  <link>
    <url>http://www.nsfc.gov.cn/Portal0/default106.htm</url>
    <description>National Natural Science Foundation of China</description>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <last_update_submitted>January 26, 2010</last_update_submitted>
  <last_update_submitted_qc>January 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2010</last_update_posted>
  <keyword>genotype</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glipizide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

